Wikipedia

User:Mr. Ibrahem/Alendronic acid

< User:Mr. Ibrahem
Mr. Ibrahem/Alendronic acid
Clinical data
Trade namesFosamax, Binosto, others
Other namesAlendronate, alendronate sodium
AHFS/Drugs.comMonograph
MedlinePlusa601011
License data
Pregnancy
category
Routes of
administration		By mouth
Drug classBisphosphonate[2]
Legal status
Legal status
Pharmacokinetic data
Bioavailability0.6%
Metabolismexcreted unchanged
Elimination half-life126 months
ExcretionKidney
Identifiers
  • sodium [4-amino-1-hydroxy-1-(hydroxy-oxido-phosphoryl)- butyl]phosphonic acid trihydrate
Chemical and physical data
FormulaC4H13NO7P2
Molar mass249.097 g·mol−1
3D model (JSmol)
  • O=P(O)(O)C(O)(CCCN)P(=O)(O)O
  • InChI=1S/C4H13NO7P2/c5-3-1-2-4(6,13(7,8)9)14(10,11)12/h6H,1-3,5H2,(H2,7,8,9)(H2,10,11,12) checkY
  • Key:OGSPWJRAVKPPFI-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Alendronic acid, sold under the brand name Fosamax among others, is a bisphosphonate medication used to treat osteoporosis and Paget's disease of bone.[2] It is taken by mouth.[2] Use is often recommended together with vitamin D, calcium supplementation, and lifestyle changes.[2]

Common side effects include constipation, abdominal pain, nausea, and acid reflux.[2] Serious side effects may include esophageal problems, osteonecrosis of the jaw, and femur fractures.[2] Use is not recommended during pregnancy or in those with poor kidney function.[4] Alendronic acid works by decreasing the activity of cells that break down bone.[2]

Alendronic acid was first described in 1978 and approved for medical use in the United States in 1995.[2][5] It is available as a generic medication.[4] In the United Kingdom, a month of medication costs the NHS about 0.41 pounds as of 2019.[4] In the United States, the wholesale cost is about US$1.16 per month.[6] In 2017, it was the 90th most commonly prescribed medication in the United States, with more than eight million prescriptions.[7][8]

References edit

  1. ^ a b "Alendronate Use During Pregnancy". Drugs.com. 22 August 2019. Archived from the original on 1 December 2020. Retrieved 17 May 2020.
  2. ^ a b c d e f g h i j "Fosamax Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 2 February 2019. Retrieved 2 February 2019.
  3. ^ "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 23 January 2021. Retrieved 9 September 2020.
  4. ^ a b c British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 710–711. ISBN 9780857113382.
  5. ^ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 523. ISBN 9783527607495. Archived from the original on 2021-03-18. Retrieved 2020-06-03.
  6. ^ "NADAC as of 2019-01-30". Centers for Medicare and Medicaid Services. Archived from the original on 2019-03-27. Retrieved 2 February 2019.
  7. ^ "The Top 300 of 2020". ClinCalc. Archived from the original on 18 March 2020. Retrieved 11 April 2020.
  8. ^ "Alendronate Sodium - Drug Usage Statistics". ClinCalc. Archived from the original on 8 July 2020. Retrieved 11 April 2020.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Alendronic_acid&oldid=1117224955"